ALZN Stock — Alzamend Neuro Inc.: Cash, EV, Pipeline

Share price

$1.89

Market cap

$9.1M

Cash

$0.7M

Enterprise value

$8.4M

Balance sheet

Cash	$0.7M
Debt	$0.0M
Net cash	$0.7M
Enterprise value	$8.4M
Basic shares	4.8M shares
Fully diluted shares	6.6M shares
Fully diluted market cap	$12.4M
Cash per share	$0.15

Cash figures as of 2026-04-30. Database snapshot: 2026-09-21.

Price history

Loading ALZN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	AL001	Phase 2	Bipolar I Disorder	—
Apr 14 - May 26	ALZN002 (autologous DCs pulsed with E22W mutant peptide).	Phase 2	Alzheimer Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

AL001

Phase 2 · Active Modality: small molecule

Partnerships University of South Florida (Licensor): exclusive worldwide licenses for AL001; 4.5% royalties on net sales. Massachusetts General Hospital / Harvard Medical School: partnership to conduct five Phase II imaging ("Lithium in Brain") trials

Indications

Alzheimer's disease (Phase 2)
Bipolar disorder (BD) (Phase 2)
Major depressive disorder (MDD) (Phase 2)
PTSD (Phase 2)

Catalysts

— fourth quarter of 2026
— fourth quarter of 2026

Status note Lead product; ionic cocrystal of lithium, oral capsule. Phase IIA MAD study completed March 2023. Phase II BD "Lithium in Brain" study initiated March 2026; MDD/PTSD studies expected to commence Q4 2026, Alzheimer's study Q1 2027.

ALZN002

Phase 2 · Active Modality: cell-based therapeutic vaccine

Target amyloid-beta

Partnerships Licensor: Standard Exclusive License Agreement with Sublicensing Terms (May 1, 2016), royalty-bearing exclusive worldwide license

Indications

Mild to moderate dementia of the Alzheimer's type (Phase 2)

Catalysts

— second quarter of 2027

Status note Phase I/IIA trial initiated April 3, 2023; IND submitted September 2022 ("study may proceed" October 31, 2022). Trial not terminated but paused pending replacement CRO; restart expected Q2 2027.

Per-asset detail extracted from the 10-Q filed 2026-09-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	AL001
Lead indication	Bipolar I Disorder
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07540338	Phase 2	Recruiting	Sponsor	ALZN	—	Bipolar I Disorder	—
NCT05834296	Phase 2	Active, not recruiting	Sponsor	ALZN	—	Alzheimer Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Alzamend Neuro, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ALZN — Alzamend Neuro Inc.